Literature DB >> 8187204

Triglyceride-rich lipoprotein interactions with Lp(a).

W J McConathy1, V N Trieu, E Koren, C S Wang, C C Corder.   

Abstract

We found a significantly reduced incidence of increased lipoprotein(a) (Lp(a)) levels in subjects with triglycerides (TG) greater than 150 mg/dl compared with those with TG levels lower than 150 mg/dl. This was the case in patients with angiographically documented coronary artery disease (CAD) and in subjects with no CAD. We explored the potential role of lipoprotein lipase (LPL) in mediating this relationship. Lp(a) and LDL2 exhibited a minimal effect on the rate constant for degradation of VLDL-TG by LPL (13% inhibition). Binding analyses indicated no differences between VLDL and LDL with respect to Lp(a) binding, and lipolysis only reduced binding by 30% at 75% degradation of VLDL-TG. Our study indicates that the inverse relationship between elevated plasma TG and Lp(a) levels is not caused by activation of LPL by Lp(a) either due to failure of Lp(a) to bind to VLDL or its lipolytic remnants. It is hypothesized that this relationship could stem from the enhanced clearance of TG-rich lipoproteins in individuals with higher levels of Lp(a) by receptor-mediated events.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8187204     DOI: 10.1016/0009-3084(94)90129-5

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  4 in total

1.  The apolipoprotein B3304-3317 peptide as an inhibitor of the lipoprotein (a):apolipoprotein B-containing lipoprotein interaction.

Authors:  V N Trieu; U Olsson; W J McConathy
Journal:  Biochem J       Date:  1995-04-01       Impact factor: 3.857

2.  Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7.

Authors:  Renato Quispe; Aditya D Hendrani; Behnoud Baradaran-Noveiry; Seth S Martin; Emily Brown; Krishnaji R Kulkarni; Maciej Banach; Peter P Toth; Eliot A Brinton; Steven R Jones; Parag H Joshi
Journal:  Arch Med Sci       Date:  2019-08-22       Impact factor: 3.318

Review 3.  The metabolism of lipoprotein (a): an ever-evolving story.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg; Rajasekhar Ramakrishnan
Journal:  J Lipid Res       Date:  2017-07-18       Impact factor: 5.922

4.  Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a).

Authors:  Xiang Zhang; Lotte C A Stiekema; Erik S G Stroes; Albert K Groen
Journal:  Lipids Health Dis       Date:  2020-05-11       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.